The removal of uremic toxins

Slides:

Advertisements

Similar presentations

Kamyar Kalantar-Zadeh Kidney International

Advertisements

Acid-base profile in patients on PD

Volume 59, Issue 2, Pages (February 2001)

Volume 54, Issue 2, Pages (August 1998)

Volume 64, Issue 4, Pages (October 2003)

Anemia management in chronic kidney disease

Acid-base profile in patients on PD

End-stage renal disease in developing countries

C-reactive protein and dialysis access

Superior dialytic clearance of β2 microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis H. Yoshida, K. Yokoyama, K.

Volume 64, Pages S3-S12 (December 2003)

Volume 53, Issue 4, Pages (April 1998)

C-reactive protein and dialysis access

Volume 76, Issue 4, Pages (August 2009)

Fluid overload and residual renal function in peritoneal dialysis: the proof of the pudding is in the eating Wim Van Biesen, Achim Jörres Kidney International

Volume 63, Issue 4, Pages (April 2003)

Kamyar Kalantar-Zadeh Kidney International

High volume peritoneal dialysis vs daily hemodialysis: A randomized, controlled trial in patients with acute kidney injury D.P. Gabriel, J.T. Caramori,

Volume 67, Issue 4, Pages (April 2005)

Volume 56, Issue 2, Pages (August 1999)

The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis Sai Subhodhini Reddy, Jean L. Holley

Joseph W. Eschbach, John W. Adamson Kidney International

The epidemiology of chronic kidney disease

Volume 60, Issue 1, Pages (July 2001)

Volume 73, Pages S5-S17 (April 2008)

Volume 65, Issue 2, Pages (February 2004)

Volume 73, Pages S94-S101 (April 2008)

Blood pressure targets in hemodialysis patients

Adsorption in hemodialysis

Joel D. Kopple, Kamyar Kalantar-Zadeh, Rajnish Mehrotra

Volume 54, Issue 2, Pages (August 1998)

Peritoneal dialysis adequacy and risk of death

Volume 54, Issue 3, Pages (September 1998)

New insights in uremic toxins

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Kidney failure and the gut: p-cresol and the dangers from within

Microbiology and outcomes of peritonitis in North America

Alternate-day dialysis may be needed for hemodialysis patients

Volume 67, Issue 6, Pages (June 2005)

A fractional dialysate collection method to estimate solute removal in continuous venovenous hemodialysis Nigel S. Kanagasundaram, A. Brett Larive, Emil.

Extracorporeal removal of toxins

Volume 73, Pages S72-S75 (April 2008)

Douglas G Matsell, Colin T White Kidney International

Joachim Böhler, M.D., Johannes Donauer, Frieder Keller

Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients B. Bammens, P. Evenepoel, H. Keuleers,

The course of the remnant kidney model in mice

Volume 60, Issue 3, Pages (September 2001)

Organ transplantation goes to the movies

Volume 70, Pages S84-S90 (November 2006)

Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms Bert Bammens, Pieter Evenepoel, Kristin.

Role of sodium in hemodialysis

Volume 80, Issue 10, Pages (November 2011)

Volume 80, Issue 10, Pages (November 2011)

Confounding factors in the assessment of delivered hemodialysis dose

Charles A. Herzog Kidney International

Quantification of free water transport in peritoneal dialysis

Bradley A. Warady, Mwaffek Bashir, Lynn A. Donaldson

Review of clinical trial experience with icodextrin

Volume 73, Issue 6, Pages (March 2008)

Volume 59, Issue 2, Pages (February 2001)

Erratum Kidney International Volume 61, Issue 4, (April 2002)

Volume 65, Issue 1, Pages (January 2004)

Hemodialysis access failure: a call to action—revisited

Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis Karl-Georg Fischer, M.D., Andreas van.

N-methyl-2-pyridone-5-carboxamide: A novel uremic toxin?

Volume 65, Issue 6, Pages (June 2004)

Volume 61, Issue 5, Pages (May 2002)

Stephen Pastan, J. Michael Soucie, William M. McClellan

Volume 60, Issue 5, Pages (November 2001)

Presentation transcript:

The removal of uremic toxins Annemieke Dhondt, M.D., Ph.D., Raymond Vanholder, Wim Van Biesen, Norbert Lameire Kidney International Volume 58, Pages S47-S59 (August 2000) DOI: 10.1046/j.1523-1755.2000.07606.x Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 1 Protein-bound uremic toxins: Chemical formula, molecular weight, and percent protein binding. Kidney International 2000 58, S47-S59DOI: (10.1046/j.1523-1755.2000.07606.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 2 Elution pattern of uremic ultrafiltrate with HPLC. The elution pattern is such that the gradient goes from hydrophilic (left on the chromatogram) to hydrophobic (right). Identified protein-bound uremic solutes: a, indoxyl sulfate; b, tryptophan; c, hippuric acid; d, indole-3-acetic acid, e, CMPF; f, internal standard. Kidney International 2000 58, S47-S59DOI: (10.1046/j.1523-1755.2000.07606.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 3 Percentage change in serum concentrations of uremic toxins after correction for hemoconcentration during dialysis with low-flux polysulfone (A), high-flux polysulfone (B), and high-flux cellulose triacetate (C). Symbols are: ▪, creatinine; □, urea; , indoxyl sulfate; , p-cresol; , CMPF. High flux polysulfone or high-flux cellulose tri-acetate vs. low-flux polysulfone. Symbols are: NS, not significant; •, P < 0.05 vs. urea; ••, P < 0.01 vs. urea; *, P < 0.05 vs. creatinine; **, P < 0.01 vs. creatinine. Kidney International 2000 58, S47-S59DOI: (10.1046/j.1523-1755.2000.07606.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 4 Weekly BUN profiles for hemodialysis and CAPD. Kidney International 2000 58, S47-S59DOI: (10.1046/j.1523-1755.2000.07606.x) Copyright © 2000 International Society of Nephrology Terms and Conditions